In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

With follow-up ranging from 1 to 11 years, use of GLP-1 agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide ...

The pneumococcal infection market is poised for steady growth, driven by a combination of high global disease burden, rising antimicrobial resistance, and expanded immunization initiatives. Analyst ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from its Phase 1/2 trial of Z-1018, the company’s experimental shingles vaccine ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors ...

Drug testing laboratories from provinces have informed the DRAP that the samples of above mentioned products have been declared the list of “spurious” drugs. It said Drug Testing Laboratories of ...

DelveInsight's, “Gastrointestinal Stromal Tumors Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline ...

As India's pioneering technology-enabled scholarship management platform, Buddy4Study is set to replicate this impact on a significant scale with INR 400 crore in scholarships for 1,00,000 students in ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

On May 12, Trump signed an executive order stating that U.S. consumers are being overcharged for prescription drugs and that “Americans must therefore have access to the most-favored-nation price.” ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...